PMID- 8667622
OWN - NLM
STAT- MEDLINE
DCOM- 19960808
LR  - 20131121
IS  - 0022-4790 (Print)
IS  - 0022-4790 (Linking)
VI  - 62
IP  - 3
DP  - 1996 Jul
TI  - Cis-diamminedichloroplatinum(II) augments expression of tumor-associated antigens 
      on human gastric cancer cell line KATO-3 and increases susceptibility and binding 
      of tumor cells to various cytotoxic effector cells.
PG  - 162-70
AB  - Previous studies have demonstrated the immunomodulatory effects of cisplatin 
      under certain conditions. The present study was designed to clarify whether 
      cisplatin modulates the expression of surface antigens, especially human 
      leukocyte antigen (HLA), on human tumor cell lines and/or augments the 
      susceptibility and binding of tumor cells to cytotoxic effector cells. A human 
      gastric cancer cell line, KATO-3, was employed. The expression of HLA and other 
      tumor-associated antigens was analyzed by flow cytometry using FITC-conjugated 
      monoclonal antibodies. The cytotoxicity of effector cells was determined by 51Cr 
      release assay. The expression of HLA class I antigen, beta2-microglobulin, 
      leukocyte function-associated antigen-1, and AC-81 adenocarcinoma-associated 
      antigen on KATO-3 increased after exposure to cisplatin at 10 micrograms/ml for 
      3-6 hr; augmentation of HLA class I subtypes -B2 and -B27 was particularly 
      prominent. Furthermore, the susceptibility and binding of KATO-3 to both 
      lymphokine-activated killer cells and KATO-3-specific cytotoxic T lymphocytes 
      significantly increased after cisplatin treatment. Cisplatin may modulate the 
      expression of tumor-associated antigens on some human tumor cells. Tumor 
      regression by cisplatin administration may depend on its direct cytotoxicity as 
      well as on its modulating effects on the expression of tumor-associated antigens, 
      subsequently leading to the activation of the immune surveillance system against 
      the tumor.
FAU - Hayashi, H
AU  - Hayashi H
AD  - First Department of Surgery, Kyoto University, Faculty of Medicine, Japan.
FAU - Nio, Y
AU  - Nio Y
FAU - Kawabata, K
AU  - Kawabata K
FAU - Araya, S
AU  - Araya S
FAU - Imamura, M
AU  - Imamura M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Surg Oncol
JT  - Journal of surgical oncology
JID - 0222643
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Antigens, Surface)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (HLA Antigens)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adjuvants, Immunologic/*pharmacology
MH  - Antigens, Neoplasm/*drug effects/immunology
MH  - Antigens, Surface/drug effects/immunology
MH  - Antineoplastic Agents/*pharmacology
MH  - Carcinoma/*immunology
MH  - Cisplatin/*pharmacology
MH  - Cytotoxicity Tests, Immunologic/methods
MH  - Dose-Response Relationship, Drug
MH  - Flow Cytometry/methods
MH  - HLA Antigens/drug effects/immunology
MH  - Humans
MH  - Killer Cells, Lymphokine-Activated/*immunology
MH  - Lymphocyte Culture Test, Mixed/methods
MH  - Stimulation, Chemical
MH  - Stomach Neoplasms/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Time Factors
MH  - Tumor Cells, Cultured
EDAT- 1996/07/01 00:00
MHDA- 2000/06/20 09:00
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - 10.1002/(SICI)1096-9098(199607)62:3<162::AID-JSO4>3.0.CO;2-5 [pii]
AID - 10.1002/(SICI)1096-9098(199607)62:3<162::AID-JSO4>3.0.CO;2-5 [doi]
PST - ppublish
SO  - J Surg Oncol. 1996 Jul;62(3):162-70. doi: 
      10.1002/(SICI)1096-9098(199607)62:3<162::AID-JSO4>3.0.CO;2-5.